Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
EXEL 
Exelixis Inc (EXEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/02/2026: EXEL (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $45.28
1 Year Target Price $45.28
| 7 | Strong Buy |
| 4 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.27% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/02/2026 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.73B USD | Price to earnings Ratio 18.31 | 1Y Target Price 45.28 |
Price to earnings Ratio 18.31 | 1Y Target Price 45.28 | ||
Volume (30-day avg) 20 | Beta 0.4 | 52 Weeks Range 31.90 - 49.62 | Updated Date 01/3/2026 |
52 Weeks Range 31.90 - 49.62 | Updated Date 01/3/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 29.63% | Operating Margin (TTM) 42.89% |
Management Effectiveness
Return on Assets (TTM) 17.73% | Return on Equity (TTM) 30.56% |
Valuation
Trailing PE 18.31 | Forward PE 15.17 | Enterprise Value 10939283841 | Price to Sales(TTM) 5.13 |
Enterprise Value 10939283841 | Price to Sales(TTM) 5.13 | ||
Enterprise Value to Revenue 4.78 | Enterprise Value to EBITDA 12.87 | Shares Outstanding 268112157 | Shares Floating 228238517 |
Shares Outstanding 268112157 | Shares Floating 228238517 | ||
Percent Insiders 2.21 | Percent Institutions 97.59 |
Upturn AI SWOT
Exelixis Inc
Company Overview
History and Background
Exelixis, Inc. was founded in 1994 and went public in 2000. It is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines for the treatment of cancer. A significant milestone was the development and commercialization of cabozantinib (marketed as COMETRIQu00ae and CABOMETYXu00ae). The company has evolved from a drug discovery engine to a fully integrated biopharmaceutical company with approved therapies and a robust pipeline.
Core Business Areas
- Oncology Therapeutics Development: Discovery, development, and commercialization of novel small molecule therapies primarily targeting cancer.
- Commercialization and Marketing: Marketing and selling approved oncology drugs and expanding their indications and global reach.
Leadership and Structure
Exelixis is led by a seasoned management team, including a CEO, CFO, Chief Medical Officer, and other key executives. The company operates with a functional organizational structure, with dedicated departments for research and development, clinical operations, commercial, regulatory affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- CABOMETYXu00ae (cabozantinib): A tyrosine kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC). Its effectiveness is measured by progression-free survival (PFS) and overall survival (OS). Key competitors in RCC include pazopanib (Votrient), axitinib (Inlyta), and nivolumab/ipilimumab (Opdivo/Yervoy). In HCC, competitors include sorafenib (Nexavar) and lenvatinib (Lenvima). In DTC, competitors include vandetanib (Caprelsa) and lenvatinib. Market share data for specific indications is proprietary but CABOMETYXu00ae is a leading therapy in its approved settings.
- COMETRIQu00ae (cabozantinib): Approved for patients with progressive, metastatic medullary thyroid cancer (MTC). Shares development and commercialization with CABOMETYXu00ae.
- XAFLOXu00ae (exagamglogene autotemcel): While not a direct Exelixis product, Exelixis has a collaboration with CRISPR Therapeutics for XAVISANTu00ae (exagamglogene autotemcel), a gene-edited therapy for sickle cell disease and beta-thalassemia. Exelixis receives royalties from this collaboration.
Market Dynamics
Industry Overview
The oncology drug market is highly competitive and rapidly evolving, driven by advancements in precision medicine, immunotherapy, and targeted therapies. There is a continuous need for novel treatments with improved efficacy and safety profiles. The market is characterized by significant R&D investment, stringent regulatory pathways, and complex reimbursement landscapes.
Positioning
Exelixis is positioned as a key player in the targeted therapy segment of oncology, particularly with its successful development and commercialization of cabozantinib. Its strengths lie in its established approved products and its ongoing efforts to expand the utility of cabozantinib into new indications and combinations, as well as its pipeline of investigational compounds.
Total Addressable Market (TAM)
The TAM for oncology drugs is vast and growing, with the global cancer therapeutics market projected to reach hundreds of billions of dollars in the coming years. Exelixis, through its approved therapies and pipeline, is targeting specific segments within this large market, including advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer, with potential expansion into other solid tumors.
Upturn SWOT Analysis
Strengths
- Established commercial success with CABOMETYXu00ae and COMETRIQu00ae.
- Strong scientific expertise in kinase inhibitors and oncology drug development.
- Robust pipeline of investigational compounds and potential for new indications for cabozantinib.
- Experienced management team and dedicated workforce.
- Strategic collaborations and partnerships.
Weaknesses
- High dependence on the success of cabozantinib and its lifecycle management.
- Limited product portfolio compared to larger pharmaceutical companies.
- Potential for pricing pressures and market access challenges.
- R&D is inherently risky and subject to clinical trial failures.
Opportunities
- Expansion of cabozantinib's indications and combination therapies.
- Development of next-generation inhibitors and novel therapeutic modalities.
- Geographic expansion into new markets.
- Strategic acquisitions or licensing opportunities.
- Leveraging real-world evidence to support product value.
Threats
- Intensifying competition from new entrants and existing players with novel therapies.
- Patent expirations and the emergence of biosimilars or generics.
- Changes in regulatory landscape and reimbursement policies.
- Adverse clinical trial results for pipeline candidates.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Bristol Myers Squibb Company (BMY)
- Bayer AG (BAYRY)
- Merck & Co., Inc. (MRK)
- Roche Holding AG (RHHBY)
Competitive Landscape
Exelixis's advantages lie in its focused expertise in oncology and its established drug, cabozantinib, which has demonstrated efficacy in multiple tumor types. However, it faces intense competition from large pharmaceutical companies with broader portfolios, extensive R&D capabilities, and established global commercial infrastructure. Larger competitors may have more resources for aggressive marketing and clinical development, posing a significant challenge to Exelixis's market share and pipeline progression.
Growth Trajectory and Initiatives
Historical Growth: Exelixis has experienced substantial historical growth, particularly in recent years, driven by the strong commercial performance of CABOMETYXu00ae. This growth has been fueled by expanding indications and market penetration. Revenue has seen a consistent upward trend.
Future Projections: Future growth projections are typically based on analyst estimates, which consider pipeline progress, potential new drug approvals, market penetration of existing drugs, and competitive landscape. Analysts generally project continued revenue growth for Exelixis, driven by the expansion of cabozantinib and advancement of its pipeline.
Recent Initiatives: Recent initiatives likely include continued clinical development for cabozantinib in new cancer types and combinations, exploring new therapeutic targets, and potentially in-licensing or acquiring early-stage assets to diversify its pipeline. Partnerships and collaborations are also ongoing strategic initiatives.
Summary
Exelixis Inc. is a strong biopharmaceutical company with a successful flagship product, CABOMETYXu00ae, driving significant revenue growth. Its core strength lies in oncology drug development and commercialization. The company needs to vigilantly manage the lifecycle of its current successful drug while effectively advancing its pipeline to mitigate dependence. Competition from larger players is a key threat to watch, as is the ongoing need for innovation and potential pipeline expansion.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations and SEC Filings (10-K, 10-Q)
- Pharmaceutical Industry Market Research Reports
- Financial News and Analysis Websites
- Analyst Reports
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Market share data and TAM estimates are subject to change and may vary depending on the source and methodology. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exelixis Inc
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2000-04-07 | CEO, President & Director Dr. Michael M. Morrissey Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1147 | Website https://www.exelixis.com |
Full time employees 1147 | Website https://www.exelixis.com | ||
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.